Howson introduced first in class oral antifellar drugs

On February 17th Scynexis announced a strategic partnership agreement with Howson Pharmaceuticals to grant the latter exclusive interest in the development and commercialization of ibrexafungerp in Greater China, including Hong Kong, Macau and Taiwan.
will make a $10 million down payment to Scynexis, as well as potential mileage and sales credits in the future.
Ibrexafungerp is a glucosin synthase inhibitor, a triamcinoid antifungal agent belonging to first in class, considered a new category of broad-spectrum oral/injected antifungal drugs.
Scynexis has submitted to the FDA a listing application for Ibrexafungerp oral preparations for the treatment of VVV candida disease (vaginal yeast infection), with PDUFA scheduled for approval on June 1, 2021.
The listing application was based on positive results from two multi-center, randomized, double-blind, placebo-controlled, Phase III VANISH-303 studies and VANISH-306 studies, and showed significant clinical cure rates compared to placebo, and showed good tolerance in female patients with 1.3 vaginal candids.
if approved, Ibrexafungerp would be the first non-virulent treatment for VFD in more than 20 years.
Ibrexafungerp's other adaptations under development include life-threatening fungal infections in hospitalized patients, such as invasive candy candide.
note: There are deletions in the original text